Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Free Radic Biol Med ; 145: 342-348, 2019 12.
Article in English | MEDLINE | ID: mdl-31600544

ABSTRACT

Nitric oxide (NO) is a key signalling molecule in the regulation of cardiometabolic function and impaired bioactivity is considered to play an important role in the onset and progression of cardiovascular and metabolic disease. Research has revealed an alternative NO-generating pathway, independent of NO synthase (NOS), in which the inorganic anions nitrate (NO3-) and nitrite (NO2-) are serially reduced to form NO. This work specifically aimed at investigating the role of commensal bacteria in bioactivation of dietary nitrate and its protective effects in a model of cardiovascular and metabolic disease. In a two-hit model, germ-free and conventional male mice were fed a western diet and the NOS inhibitor l-NAME in combination with sodium nitrate (NaNO3) or placebo (NaCl) in the drinking water. Cardiometabolic parameters including blood pressure, glucose tolerance and body composition were measured after six weeks treatment. Mice in both placebo groups showed increased body weight and fat mass, reduced lean mass, impaired glucose tolerance and elevated blood pressure. In conventional mice, nitrate treatment partly prevented the cardiometabolic disturbances induced by a western diet and l-NAME. In contrast, in germ-free mice nitrate had no such beneficial effects. In separate cardiovascular experiments, using conventional and germ-free animals, we assessed NO-like signalling downstream of nitrate by administration of sodium nitrite (NaNO2) via gavage. In this acute experimental setting, nitrite lowered blood pressure to a similar degree in both groups. Likewise, isolated vessels from germ-free mice robustly dilated in response to the NO donor sodium nitroprusside. In conclusion, our findings demonstrate the obligatory role of host-microbiota in bioactivation of dietary nitrate, thus contributing to its favourable cardiometabolic effects.


Subject(s)
Cardiovascular Diseases/genetics , Cardiovascular System/metabolism , Host Microbial Interactions/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/microbiology , Cardiovascular Diseases/pathology , Cardiovascular System/microbiology , Cardiovascular System/pathology , Diet, Western/adverse effects , Humans , Mice , NG-Nitroarginine Methyl Ester/pharmacology , Nitrates/pharmacology , Nitric Oxide Synthase/genetics , Nitrites/pharmacology , Signal Transduction/drug effects
2.
Redox Biol ; 15: 182-191, 2018 05.
Article in English | MEDLINE | ID: mdl-29268201

ABSTRACT

RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesirable side effects and development of tolerance. In this study, we evaluated NO release capability and cardiovascular effects of the newly synthesized organic nitrate 1, 3-bis (hexyloxy) propan-2-yl nitrate (NDHP). METHODS: A combination of in vitro and in vivo approaches was utilized to assess acute effects of NDHP on NO release, vascular reactivity and blood pressure. The therapeutic value of chronic NDHP treatment was assessed in an experimental model of angiotensin II-induced hypertension in combination with NOS inhibition. RESULTS: NDHP mediates NO formation in both cell-free system and small resistance arteries, a process which is catalyzed by xanthine oxidoreductase. NDHP-induced vasorelaxation is endothelium independent and mediated by NO release and modulation of potassium channels. Reduction of blood pressure following acute intravenous infusion of NDHP was more pronounced in hypertensive rats (two-kidney-one-clip model) than in normotensive sham-operated rats. Toxicological tests did not reveal any harmful effects following treatment with high doses of NDHP. Finally, chronic treatment with NDHP significantly attenuated the development of hypertension and endothelial dysfunction in rats with chronic NOS inhibition and angiotensin II infusion. CONCLUSION: Acute treatment with the novel organic nitrate NDHP increases NO formation, which is associated with vasorelaxation and a significant reduction of blood pressure in hypertensive animals. Chronic NDHP treatment attenuates the progression of hypertension and endothelial dysfunction, suggesting a potential for therapeutic applications in cardiovascular disease.


Subject(s)
Hypertension/drug therapy , Kidney/drug effects , Nitric Oxide/metabolism , Nitro Compounds/administration & dosage , Angiotensin II/metabolism , Animals , Blood Pressure/drug effects , Disease Models, Animal , Endothelium, Vascular/drug effects , Endothelium, Vascular/pathology , Humans , Hypertension/metabolism , Hypertension/pathology , Kidney/metabolism , Kidney/pathology , Male , Nitric Oxide Synthase/genetics , Oxidative Stress/drug effects , Rats , Rats, Inbred Dahl/genetics , Xanthine Dehydrogenase/genetics , Xanthine Dehydrogenase/metabolism
3.
Redox Biol ; 13: 163-169, 2017 10.
Article in English | MEDLINE | ID: mdl-28578274

ABSTRACT

In this report, we describe the synthesis and characterization of 1,3-bis(hexyloxy)propan-2-yl nitrate (NDHP), a novel organic mono nitrate. Using purified xanthine oxidoreductase (XOR), chemiluminescence and electron paramagnetic resonance (EPR) spectroscopy, we found that XOR catalyzes nitric oxide (NO) generation from NDHP under anaerobic conditions, and that thiols are not involved or required in this process. Further mechanistic studies revealed that NDHP could be reduced to NO at both the FAD and the molybdenum sites of XOR, but that the FAD site required an unoccupied molybdenum site. Conversely, the molybdenum site was able to reduce NDHP independently of an active FAD site. Moreover, using isolated vessels in a myograph, we demonstrate that NDHP dilates pre-constricted mesenteric arteries from rats and mice. These effects were diminished when XOR was blocked using the selective inhibitor febuxostat. Finally, we demonstrate that NDHP, in contrast to glyceryl trinitrate (GTN), is not subject to development of tolerance in isolated mesenteric arteries.


Subject(s)
Nitric Oxide/metabolism , Nitro Compounds/chemical synthesis , Vasodilator Agents/chemical synthesis , Xanthine Dehydrogenase/metabolism , Animals , Electron Spin Resonance Spectroscopy , Mesenteric Arteries/drug effects , Mesenteric Arteries/physiology , Mice , Mice, Inbred C57BL , Muscle Contraction , Nitric Oxide/chemistry , Nitro Compounds/chemistry , Nitro Compounds/pharmacology , Rats , Vasodilator Agents/chemistry , Vasodilator Agents/pharmacology , Xanthine Dehydrogenase/chemistry
4.
Rev. bras. farmacogn ; 26(5): 595-600, Sept.-Oct. 2016. tab, graf
Article in English | LILACS | ID: lil-796136

ABSTRACT

ABSTRACT Effects of treatment with the bark flour of Passiflora edulis Sims, Passifloraceae, were evaluated. Adult male Wistar rats were treated for 30 days (130 mg/kg, p.o.) with the albedo flour, flavedo and full bark of P. edulis, corresponding to albedo associated with flavedo. Behavioral response observed after treatment with bark flour P. edulis showed sedative effects by the reduction of exploratory activity and increased duration of immobility in the open field test for the group of animals that received the albedo flour associated with the flavedo. Sedative effects were observed in the absence of motor incoordination or muscle relaxation. Food intake of experimental animals was not changed, but the weight gain was decreased both in animals that received only albedo flour, and in those who received the full bark flour. The full bark flour of Passiflora showed sedative effects, without anxiolytic effect detectable and muscle relaxation or motor incoordination, and reduces body weight gain.

SELECTION OF CITATIONS
SEARCH DETAIL
...